Aggressive administration of recombinant oncotoxin AR209 (anti-ErB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1628-1633

  Skrepnik, N ^a   Zieske, A W ^a   Robert, E ^a   Bravo, J C ^a   Mera, R ^a   Hunt, J D ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Exotoxin A; HER 2; Immunotoxin; neu; Pseudomonas

Indexed keywords

EXOTOXIN; IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CELL KILLING; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TARGET CELL;

ANIMALS; ANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; RECOMBINANT PROTEINS;

EID: 0032169118     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00176-2     Document Type: Article

References (30)

1. 1. Cancer Facts & Figures - 1997. Atlanta, Georgia, American Cancer Society, 1997.
2. 2. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, J. P. Lippincott, 1993, 673-730.
3. 3. Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. In Haskell CM, ed. Current Problems in Cancer. St. Louis, Mosby-Year Book, 1991, 63-104.
4. 4. Ihde DC, Minna JD. Non-small cell lung cancer. Part II: Treatment. In Haskell CM, ed. Current Problems in Cancer. St. Louis, Mosby-Year Book, 1991, 107-154.
5. 5. De Vita Jr VT, Hellman S, Rosenberg, SA (eds). Biologic Therapy of Cancer. Philadelphia, J. B. Lippincott, 1995.
6. 6. Pai LH, Pastan I. Section 20.2. Immunotoxins and recombinant toxins. In DeVita Jr VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia, J. B. Lippincott, 1995, 521-533.
7. 7. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci (USA) 1992, 89, 5867-5871.
8. 8. Kasprzyk PG, Sullivan TL, Hunt JD, et al. Activity of Anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification. Clin Cancer Res 1996, 2, 75-80.
9. 9. Skrepnik N, Araya JC, Qian Z, et al. Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Clin Cancer Res 1996, 2, 1851-1857.
10. 10. Siegfried JM, Owens SE. Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. Cancer Res 1988, 48, 4976-4981.
11. 11. DeMichele MAA, Davis ALG, Hunt JD, Landreneau RJ, Siegfried JM. Expression of messenger RNA for three bombesin receptor subtypes in human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994, 11, 66-74.
12. 12. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG, Pretlow TP. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res 1991, 51, 3814-3817.
13. 13. Fridman R, Kibbey MC, Royce LS, et al. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with matrigel. J Natl Cancer Inst 1991, 83, 769-774.
14. 14. Hamide JP, Qian Z, Xu H, et al. Percutaneous implantation of non-small cell lung carcinoma: technique and observations. Academ Radiol 1997, 4, 629-633.
15. 15. Schreiber H, Ward PL, Rowley DA, Stauss HL. Unique tumor-specific antigens. Ann Rev Immunol 1988, 6, 465-483.
16. 16. Munro S, Pellham HRB. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987, 4, 899-907.
17. 17. Lynch Jr TJ. Immunotoxin therapy of small cell lung cancer. N901-blocked ricin for relapsed small cell lung cancer. Chest 1993, 103, 4365-4395.
18. 18. Grossbard ML, Lambert JM, Goldmacher US, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993, 11, 726-737.
19. 19. Grossbard ML, Gribben JG, Freedman AS, et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-Cell non-Hodgkin's lymphoma, Blood 1993, 81, 2263-2271.
20. 20. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycoxylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993, 82, 2624-2633.
21. 21. Grossbard ML, Freedman AS, Ritz J, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992, 79, 576-585.
22. 22. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989, 8, 8570-8576.
23. 23. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988, 48, 7022-7032.
24. 24. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, Fitzgerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (London) 1989, 339, 394-397.
25. 25. Reiter Y, Brinkmann U, Jung SH, et al. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 1994, 269, 18327-18331.
26. 26. Blumenthal RD, Stein R, Sharkey RM, et al. Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon. Cancer Res 1996, 56, 3508-3515.
27. 27. Sung C, Dedrick RL, Hall WA, Johnson PA, Youle RJ. The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography. Cancer Res 1993, 53, 2092-2099.
28. 28. Rippley RK, Stokes CL. Effects of cellular pharmacology on drug distribution in tissues. Biophys J 1995, 69, 825-839.
29. 29. Freeman SM, Abbound CN, Whartenby KA, et al. The "Bystander Effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993, 53, 5274-5283.
30. 30. Hoganson DK, Batra RK, Olsen JC, Boucher RC. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res 1996, 56, 1315-1323.